Monte Rosa Therapeutics Valuation
Is GLUE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GLUE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GLUE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GLUE's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GLUE?
Key metric: As GLUE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is GLUE's PS Ratio? | |
|---|---|
| PS Ratio | 34.3x |
| Sales | US$14.98m |
| Market Cap | US$513.61m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 21x |
| Enterprise Value/EBITDA | -2.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does GLUE's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.7x | ||
SPPI Spectrum Pharmaceuticals | 8.2x | 35.5% | US$209.9m |
ZNTL Zentalis Pharmaceuticals | 5.6x | 37.0% | US$223.1m |
PYXS Pyxis Oncology | 7.7x | 14.0% | US$227.2m |
GOSS Gossamer Bio | 1.4x | 15.1% | US$157.6m |
GLUE Monte Rosa Therapeutics | 34.3x | 47.5% | US$513.6m |
Price-To-Sales vs Peers: GLUE is expensive based on its Price-To-Sales Ratio (34.3x) compared to the peer average (4.9x).
Price to Sales Ratio vs Industry
How does GLUE's PS Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: GLUE is expensive based on its Price-To-Sales Ratio (34.3x) compared to the US Biotechs industry average (10.1x).
Price to Sales Ratio vs Fair Ratio
What is GLUE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 34.3x |
| Fair PS Ratio | 24.1x |
Price-To-Sales vs Fair Ratio: GLUE is expensive based on its Price-To-Sales Ratio (34.3x) compared to the estimated Fair Price-To-Sales Ratio (24.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$8.35 | US$16.43 +96.7% | 14.1% | US$20.00 | US$14.00 | n/a | 7 |
| Nov ’25 | US$8.90 | US$15.71 +76.6% | 25.8% | US$20.00 | US$7.00 | n/a | 7 |
| Oct ’25 | US$5.30 | US$14.57 +174.9% | 27.2% | US$20.00 | US$7.00 | n/a | 7 |
| Sep ’25 | US$6.17 | US$14.57 +136.2% | 27.2% | US$20.00 | US$7.00 | n/a | 7 |
| Aug ’25 | US$4.37 | US$15.00 +243.2% | 23.6% | US$20.00 | US$9.00 | n/a | 7 |
| Jul ’25 | US$3.94 | US$15.00 +280.7% | 23.6% | US$20.00 | US$9.00 | n/a | 7 |
| Jun ’25 | US$4.12 | US$15.00 +264.1% | 23.6% | US$20.00 | US$9.00 | n/a | 7 |
| May ’25 | US$5.94 | US$15.43 +159.7% | 24.7% | US$20.00 | US$9.00 | n/a | 7 |
| Apr ’25 | US$7.14 | US$15.71 +120.1% | 26.7% | US$22.00 | US$9.00 | n/a | 7 |
| Mar ’25 | US$6.30 | US$16.00 +154.0% | 24.8% | US$22.00 | US$10.00 | n/a | 7 |
| Feb ’25 | US$4.95 | US$15.14 +205.9% | 35.4% | US$22.00 | US$5.00 | n/a | 7 |
| Jan ’25 | US$5.65 | US$15.14 +168.0% | 35.4% | US$22.00 | US$5.00 | n/a | 7 |
| Dec ’24 | US$3.12 | US$16.50 +428.8% | 37.4% | US$26.00 | US$5.00 | n/a | 8 |
| Nov ’24 | US$3.42 | US$18.50 +440.9% | 35.9% | US$26.00 | US$5.00 | US$8.90 | 8 |
| Oct ’24 | US$4.79 | US$22.13 +361.9% | 20.9% | US$31.00 | US$15.00 | US$5.30 | 8 |
| Sep ’24 | US$6.20 | US$20.89 +236.9% | 26.7% | US$31.00 | US$11.00 | US$6.17 | 9 |
| Aug ’24 | US$6.90 | US$20.89 +202.7% | 26.7% | US$31.00 | US$11.00 | US$4.37 | 9 |
| Jul ’24 | US$6.85 | US$20.89 +204.9% | 26.7% | US$31.00 | US$11.00 | US$3.94 | 9 |
| Jun ’24 | US$7.55 | US$20.89 +176.7% | 26.7% | US$31.00 | US$11.00 | US$4.12 | 9 |
| May ’24 | US$5.24 | US$21.67 +313.5% | 31.8% | US$36.00 | US$11.00 | US$5.94 | 9 |
| Apr ’24 | US$7.79 | US$21.67 +178.1% | 31.8% | US$36.00 | US$11.00 | US$7.14 | 9 |
| Mar ’24 | US$6.16 | US$21.89 +255.3% | 31.8% | US$37.00 | US$12.00 | US$6.30 | 9 |
| Feb ’24 | US$7.23 | US$21.89 +202.8% | 31.8% | US$37.00 | US$12.00 | US$4.95 | 9 |
| Jan ’24 | US$7.61 | US$23.11 +203.7% | 35.0% | US$37.00 | US$12.00 | US$5.65 | 9 |
| Dec ’23 | US$8.89 | US$23.11 +160.0% | 35.0% | US$37.00 | US$12.00 | US$3.12 | 9 |
| Nov ’23 | US$9.03 | US$23.56 +160.9% | 32.3% | US$37.00 | US$15.00 | US$3.42 | 9 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
IQVIA Holdings
US$34.7b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV
US$194.38
7D
-8.1%
1Y
-7.2%
Collegium Pharmaceutical
US$959.4m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$30.00
7D
-0.6%
1Y
15.5%
ANI Pharmaceuticals
US$1.1b
A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
ANIP
US$55.10
7D
-7.9%
1Y
6.6%